Gliclazide (JAN)
Gliclazide (JAN) Brand names, Gliclazide (JAN) Analogs
- 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
- 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
- Diamicron
- Gliclazida [INN-Spanish]
- Gliclazide (JAN)
- Gliclazide [BAN:DCF:INN:JAN]
- Gliclazidum [INN-Latin]
- Glimicron
- Glimicron (TN)
- N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea
- Nordialex
Gliclazide (JAN) Brand Names Mixture
- No information avaliable
Gliclazide (JAN) Chemical_Formula
C15H21N3O3S
Gliclazide (JAN) RX_link
No information avaliable
Gliclazide (JAN) fda sheet
Gliclazide (JAN) msds (material safety sheet)
Gliclazide (JAN) Synthesis Reference
No information avaliable
Gliclazide (JAN) Molecular Weight
323.412 g/mol
Gliclazide (JAN) Melting Point
181 oC
Gliclazide (JAN) H2O Solubility
No information avaliable
Gliclazide (JAN) State
Solid
Gliclazide (JAN) LogP
2.418
Gliclazide (JAN) Dosage Forms
Tablet
Gliclazide (JAN) Indication
For the treatment of Diabetes mellitus
Gliclazide (JAN) Pharmacology
Gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates beta cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall it potentiates insulin release and improves insulin dynamics.
Gliclazide (JAN) Absorption
Rapidly and well absorbed but may have wide inter- and intra-individual variability.
Gliclazide (JAN) side effects and Toxicity
LD50=3000 mg/kg (orally in mice)
Gliclazide (JAN) Patient Information
No information avaliable
Gliclazide (JAN) Organisms Affected
Humans and other mammals
